Abstract
Objective
We evaluated the uptake of 2-deoxy-2-18F-fluoro-d-glucose (FDG) and l-[methyl-11C]-methionine (MET) in patients with newly diagnosed intracranial meningiomas and correlated the results with tumor proliferation.
Methods
Data from 22 patients with newly diagnosed intracranial meningioma (12 grade I and 10 grade II) who underwent both FDG and MET brain PET/CT studies were retrospectively analyzed. The PET images were evaluated by a qualitative method and semiquantitative analysis using standardized uptake value (SUV) (SUVmax and SUVpeak) and tumor-to-reference tissue ratio (Tmax/N ratio and Tpeak/N ratio). Proliferative activity as indicated by the Ki-67 index was estimated in tissue specimens.
Results
MET PET/CT showed a higher detection rate of meningioma than did FDG PET/CT (100 vs. 46%, respectively). The Tmax/N ratio and Tpeak/N ratio on MET PET/CT were significantly higher than those on FDG PET/CT (p < 0.001 and p < 0.001, respectively). There was a significant difference between grades I and II with respect to FDG SUVmax (p = 0.003), FDG SUVpeak (p = 0.003), FDG Tmax/N ratio (p = 0.02), FDG Tpeak/N ratio (p = 0.006), MET SUVmax (p = 0.002), MET SUVpeak (p = 0.002), MET Tmax/N ratio (p = 0.002), and MET Tpeak/N ratio (p = 0.002). There was a significant correlation between Ki-67 index and FDG PET/CT for SUVmax (p = 0.02), SUVpeak (p = 0.005), and Tpeak/N ratio (p = 0.05) and between Ki-67 index and MET PET/CT for SUVmax (p = 0.004), SUVpeak (p = 0.007), Tmax/N ratio (p = 0.002), and Tpeak/N ratio (p = 0.004).
Conclusion
MET PET/CT showed a high sensitivity compared with FDG PET/CT for detection of newly diagnosed WHO grades I and II intracranial meningiomas. Both FDG and MET uptake were found to be useful for evaluating tumor proliferation in meningiomas.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Marosi C, Hassler M, Roessler K, Reni M, Sant M, Mazza E, et al. Meningioma. Crit Rev Oncol Hematol. 2008;67:153–71.
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803–20.
Maier H, Ofner D, Hittmair A, Kitz K, Budka H. Classic, atypical, and anaplastic meningioma: three histopathological subtypes of clinical relevance. J Neurosurg. 1992;77:616–23.
Goyal LK, Suh JH, Mohan DS, Prayson RA, Lee J, Barnett GH. Local control and overall survival in atypical meningioma: a retrospective study. Int J Radiat Oncol Biol Phys. 2000;46:57–61.
Cremerius U, Striepecke E, Henn W, Weis J, Mull M, Lippitz B, et al. 18FDG-PET in intracranial meningiomas versus grading, proliferation index, cellular density and cytogenetic analysis. Nuklearmedizin. 1994;33:144–9.
Lippitz B, Cremerius U, Mayfrank L, Bertalanffy H, Raoofi R, Weis J, et al. PET-study of intracranial meningiomas: correlation with histopathology, cellularity and proliferation rate. Acta Neurochir Suppl. 1996;65:108–11.
Lee JW, Kang KW, Park SH, Lee SM, Paeng JC, Chung JK, et al. 18F-FDG PET in the assessment of tumor grade and prediction of tumor recurrence in intracranial meningioma. Eur J Nucl Med Mol Imaging. 2009;36:1574–82.
Iuchi T, Iwadate Y, Namba H, Osato K, Saeki N, Yamaura A, et al. Glucose and methionine uptake and proliferative activity in meningiomas. Neurol Res. 1999;21:640–4.
Di Chiro G, Hatazawa J, Katz DA, Rizyoli HV, De Michele DJ. Glucose utilization by intracranial meningiomas as an index of tumor aggressivity and probability of recurrence: a PET study. Radiology. 1987;164:521–6.
Liu RS, Chang CP, Guo WY, Pan DH, Ho DM, Chang CW, et al. 1-11C-acetate versus 18F-FDG PET in detection of meningioma and monitoring the effect of gamma-knife radiosurgery. J Nucl Med. 2010;51:883–91.
Okuchi S, Okada T, Yamamoto A, Kanagaki M, Fushimi Y, Okada T, et al. Grading meningioma: a comparative study of thallium-SPECT and FDG-PET. Medicine. 2015;94:e549.
Arita H, Kinoshita M, Okita Y, Hirayama R, Watabe T, Ishohashi K, et al. Clinical characteristics of meningiomas assessed by 11C-methionine and 18F-fluorodeoxyglucose positron-emission tomography. J Neurooncol. 2012;107:379–86.
Chung JK, Kim YK, Kim SK, Lee YJ, Paek S, Yeo JS, et al. Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo-or isometabolic on 18F-FDG-PET. Eur J Nucl Med Mol Imaging. 2002;29:176–82.
Hatazawa J, Ishiwata K, Itoh M, Kameyama M, Kubota K, Ido T, et al. Quantitative evaluation of l-[methyl-C-11] methionine uptake in tumor using positron emission tomography. J Nucl Med. 1989;30:1809–13.
Ogawa T, Shishido F, Kanno I, Inugami A, Fujita H, Murakami M, et al. Cerebral gliomas: evaluation with methionine-PET. Radiology. 1993;186:45–53.
Gudjonsson O, Blomquist E, Lilja A, Ericson H, Bergström M, Nybrg G. Evaluation of the effect of high-energy proton irradiation treatment on meningioma by means of 11C-l-methionine PET. Eur J Nucl Med. 2000;27:1793–9.
Ikeda H, Tsuyuguchi N, Kunihiro N, Ishibashi K, Goto T, Ohata K. Analysis of progression and recurrence of meningioma using 11C-methionine PET. Ann Nucl Med. 2013;27:772–80.
Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology. 2004;231:305–32.
Rutten I, Cabay JE, Withofs N, Lemaire C, Aerts J, Baart V, et al. PET/CT of skull base meningiomas using 2-18F-fluoro-l-tyrosine: initial report. J Nucl Med. 2007;48:720–5.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mitamura, K., Yamamoto, Y., Norikane, T. et al. Correlation of 18F-FDG and 11C-methionine uptake on PET/CT with Ki-67 immunohistochemistry in newly diagnosed intracranial meningiomas. Ann Nucl Med 32, 627–633 (2018). https://doi.org/10.1007/s12149-018-1284-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12149-018-1284-6